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Background.  Several diazabicyclooctanes (DBOs) are under development as inhibitors of Class A and 30 
C -lactamases.  Inhibition of OXA (Class D) carbapenemases is variable, with those of Acinetobacter 31 
spp. remaining notably resistant. We describe a novel DBO, WCK 4234 (Wockhardt), with distinctive 32 
activity against OXA carbapenemases.  Methods.  MICs of imipenem and meropenem were 33 
determined by CLSI agar dilution with WCK 4234 added at 4 or 8 mg/L.  Test organisms were clinical 34 
Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa with carbapenemases 35 
or carbapenem resistance via porin loss plus AmpC or ESBL activity. AmpC mutants were also tested.  36 
Results.  WCK 4234, which lacked direct antibacterial activity, strongly potentiated imipenem and 37 
meropenem against Enterobacteriaceae with OXA-48/181, KPC enzymes, or with combinations of 38 
impermeability and AmpC or ESBL activity, with MICs reduced to <2 mg/L in almost all cases.   39 
Carbapenems likewise were potentiated against P. aeruginosa (n=2) with OXA-181 enzyme, with 40 
MICs reduced from 64-128 mg/L to 2-8 mg/L and against A. baumannii with OXA carbapenemases, 41 
particularly OXA-23 or hyperproduced OXA-51, with MICs reduced to <2 mg/L for 9/10 42 
acinetobacters with OXA-23 enzyme. Carbapenems were not potentiated against 43 
Enterobacteriaceae or non-fermenters with metallo--lactamases.  Conclusion.  WCK 4234 44 
distinctively overcame resistance mediated by OXA-type carbapenemases, including in A. baumannii.  45 
It behaved similarly to other DBOs against strains with KPC carbapenemases or combinations of 46 
impermeability and ESBL or AmpC activity.  47 
48 
Introduction 49 
-Lactam--lactamase inhibitor combinations offer one of the best prospects for overcoming the 50 
diversity of potent lactamases now challenging patient management. Interest centres on 51 
diazabicyclooctanes (DBOs) and boronates.1  52 
 The first DBO to be commercialised, avibactam, is licensed in combination with ceftazidime 53 
and under Phase II trials with aztreonam.2   A second analogue, relebactam, is in phase III trials 54 
combined with imipenem-cilastatin.1 Two further analogue – zidebactam (combined with cefepime)3 55 
and OP0595/RG60804– are in earlier-stage clinical development.  All these DBOs inhibit class A and C 56 
-lactamases, including ESBLs, KPC and AmpC types, whereas none inhibits metallo- (Class B) -57 
lactamases (MBL), though these may be out-flanked by using aztreonam, which is stable to MBLs, as 58 
the partner -lactam,5 or where the DBO itself has antibacterial activity, as with RG6080 (which is 59 
active versus Enterobacteriaceae) or zidebactam (which is active against P. aeruginosa as well as 60 
Enterobacteriaceae).3,4   Class D carbapenemases are variably overcome by DBOs.  Avibactam 61 
inhibits OXA-48-like enzymes6 and is combined with ceftazidime and aztreonam,6,7 which anyway are 62 
stable; zidebactam does not inhibit these -lactamases, but is combined with cefepime, which 63 
likewise is stable;8 relebactam does not inhibit and does not potentiate imipenem against 64 
Enterobacteriaceae with OXA-48-like -lactamases.9 None of the published analogues protects 65 
against the OXA-23, -40, -51 and -58 type carbapenemases that cause most carbapenem resistance 66 
in Acinetobacter spp.    67 
We describe here a novel DBO, WCK 4234 which is being developed for combination with 68 
meropenem as WCK 5999 (figure 1), with distinctive activity against Class D lactamases, including 69 
those of Acinetobacter spp., as well as class A and C types. 70 
 71 
Materials and methods 72 
Isolates 73 
Clinical isolates (n=348) were referred by UK diagnostic laboratories to PHE for investigation of 74 
resistance or were collected in during resistance surveys.  They were identified using API20E or 75 
API20NE strips (bioMerieux, Marcy l'Etoile, France) or by MALDI-ToF mass spectroscopy (Maldi-76 
Biotyper, Bruker, Bremen, Germany), except for A. baumannii isolates, which were identified by PCR 77 
detection of blaOXA-51-like.10 Carbapenemase genes were identified by PCR or sequencing. The 78 
species split among Enterobacteriaceae with different resistance mechanisms is shown in Table 1.  79 
We also tested previously-described AmpC inducibility mutant series of Enterobacteriaceae and P. 80 
aeruginosa mutants with different combinations of AmpC inducibility and porin OprD expression. 11,12 81 
  82 
Antibiotics and susceptibility testing 83 
MICs of imipenem (Wockhardt, Aurangabad, India), meropenem (Sequoia Research Products, 84 
Pangbourne, UK) and (as a control) ciprofloxacin combined with WCK 4234, (Wockhardt) at 0, 4 or 8 85 
mg/L were determined by CLSI agar dilution13 using Mueller-Hinton agar from Oxoid (Thermofisher, 86 
Basingstoke, UK). Ceftazidime (Sigma-Aldrich, Poole, UK), with and without avibactam 4 mg/L 87 
(Wockhardt), was tested in parallel as a comparator, as was ertapenem (Wockhardt).  Tests were 88 
run once with the control strains advised by CLSI and further AMRHAI internal controls with ESBLs 89 
and carbapenemases. 90 
 91 
Results  92 
Enterobacteriaceae 93 
Susceptibility phenotypes of the clinical isolates to established lactams were as expected. Thus, 94 
control Enterobacteriaceae without acquired resistance were susceptible to all three carbapenem 95 
analogues, as were isolates with only ESBL or AmpC activity, whereas carbapenem resistance was 96 
seen in isolates with KPC, MBL, OXA-48 and -181 enzymes and - particularly to ertapenem - in those 97 
with combinations of porin loss and AmpC or ESBL activity (Table 2).  Carbapenem MICs were widely 98 
scattered for isolates with OXA-48-like (i.e. OXA-48 or 181) carbapenemases whereas isolates with 99 
KPC enzymes or MBLs more consistently had high-level resistance. Ceftazidime resistance was 100 
universal in all groups except for the controls, which were all susceptible, and those with OXA-48-101 
like enzymes, where ceftazidime MICs were bimodally distributed, probably reflecting the co-102 
production or not of ESBLs.  Ciprofloxacin resistance was widespread but variable within groups, as 103 
reflected by bimodal MIC distributions. 104 
WCK 4234 lacked direct antibacterial activity at up to 128 mg/L and did not potentiate 105 
ciprofloxacin (not shown).  We therefore consider that its interactions with carbapenems reflected 106 
lactamase inhibition, not PBP inhibition or permeabilisation.  Summary MIC data for the clinical 107 
isolates, illustrating these interactions with imipenem and meropenem, are shown in Table 2, with 108 
full MIC distributions for isolates with KPC and OXA-48-like enzymes in Table 3.  109 
WCK 4234, at 4 or 8 mg/L, caused four-fold or greater reductions in the geometric mean 110 
MICs of imipenem and meropenem for (i) Enterobacteriaceae isolates with combinations of high-level 111 
AmpC or ESBL activity and impermeability and (ii) Enterobacteriaceae with KPC, OXA-48 and OXA-112 
181 carbapenemases. In all these cases the geometric mean MICs of imipenem and meropenem fell 113 
from the intermediate or (generally) resistant range to the susceptible (i.e. <1 mg/L) and, except for 114 
a few isolates with KPC carbapenemases, the top-most MICs remained <2+4 mg/L, corresponding to 115 
intermediate for the unprotected carbapenems on CLSI criteria (Table 3).   This ‘target’ of four-fold 116 
reduction of geometric mean MIC was only narrowly missed for the carbapenem-susceptible AmpC 117 
isolates (Table 2), and four- to eight- fold potentiation of imipenem and meropenem was widely 118 
seen for the AmpC-inducible and -derepressed Enterobacteriaceae organisms in the isogenic mutant 119 
series, though not for the corresponding AmpC-deficient mutants (not shown). These data support 120 
the view that AmpC enzymes have a weak protective effect against carbapenems, but only confer 121 
resistance if permeability is reduced.14 122 
 Little potentiation of carbapenems, in terms of geometric mean MICs, was seen for control 123 
Enterobacteriaceae, lacking potent lactamases, or for carbapenem-susceptible ESBL or AmpC 124 
producers, all of which were anyway susceptible to imipenem and meropenem.  Nevertheless, for 125 
reasons not understood, WCK 4234, 4 or 8 mg/L, engendered a c. two-fold lowering in geometric 126 
mean MICs for imipenem, but not meropenem.  No potentiation of carbapenems by WCK 4234 was 127 
seen for MBL-producing Enterobacteriaceae, which were consistently resistant to carbapenems and 128 
their WCK 4234 combinations.   129 
Ceftazidime-avibactam achieved similarly broad activity to carbapenem-WCK 4234 130 
combinations against the Enterobacteriaceae groups. At its CLSI and EUCAST breakpoint of 8+4 mg/, 131 
and asides from MBL producers, resistance was confined to 1/35 carbapenem-resistant AmpC 132 
strains and 1/31 with a KPC carbapenemase.  Geometric mean MICs of ceftazidime-avibactam 133 
nevertheless were higher than those of the carbapenem-WCK 4234 combinations for virtually all 134 
test groups of Enterobacteriaceae. 135 
 136 
P. aeruginosa 137 
 MICs of carbapenems for AmpC-hyperproducing, OprD-deficient P. aeruginosa isolates were 138 
reduced four-fold or more by WCK 4234 at 4 or 8 mg/L (Table 2) though the potentiated values 139 
often only fell into the intermediate range (4-8 mg/L, on CLSI criteria).   Weaker dose-dependent 140 
potentiation, with two- or three-fold reductions in geometric mean MICs, stronger for imipenem 141 
than meropenem, was seen for all other P. aeruginosa groups except MBL producers, which 142 
remained highly resistant regardless of WCK 4234.   These small generalised MIC reductions for 143 
imipenem, seen also with relebactam, accord with the view that inducible or derepressed AmpC 144 
ordinarily gives a small degree of protection against imipenem.9,15  145 
   With only two representatives it is impossible to be definitive about P. aeruginosa with 146 
OXA-48-like carbapenemases; nevertheless, the imipenem and meropenem MICs for these two 147 
organisms, both with OXA-181 enzyme, were reduced from >64 mg/L to 2-8 mg/L by WCK 4234 at 4 148 
or 8 mg/L (Table 3).  Potentiation was also seen for AmpC-inducible and –derepressed laboratory 149 
strains, including those deficient for porin OprD, but not for AmpC-deficient mutants  (Table 4).  150 
 Avibactam reduced the geometric mean MIC of ceftazidime by four-fold or more for the 151 
AmpC-derepressed P. aeruginosa groups, with a two-fold effect for cystic fibrosis isolates and little 152 
or no effect for other groups. The two OXA-181 isolates were anyway susceptible to ceftazidime at 153 
2-4 mg/L, with these values unaltered by avibactam (Table 2).   154 
 155 
A. baumannii 156 
WCK 4234 achieved strong potentiation of both imipenem and meropenem against isolates with 157 
class D carbapenemases, with geometric mean MICs reduced 8- to 40- fold (Table 2).  For isolates 158 
with OXA-23 – the commonest carbapenemase in A. baumannii in much of the world16 – imipenem 159 
and meropenem MICs were reduced to the 2 mg/L CLSI breakpoint, or below, by WCK 4234 at 8 160 
mg/L for 9 of 10 cases (Table 3), with this target also achieved by 4 mg/L WCK 4234 in the case of 161 
meropenem.  Similarly-good potentiation was seen also for isolates with hyper-produced 162 
chromosomal OXA-51 enzymes, whereas WCK 4234-potentiated MICs mostly remained in the 163 
intermediate and resistant ranges for isolates with OXA-24/40 -lactamases and, for meropenem 164 
only, for those with OXA-58 (Table 3).  WCK 4234 had minimal effect on the carbapenem MICs for 165 
control Acinetobacter isolates and for those with AmpC and metallo carbapenemases. Avibactam 166 
did not potentiate ceftazidime against any group of A. baumannii isolates (Table 2). 167 
 168 
Discussion  169 
Carbapenemases present a growing clinical problem, which is compounded by their biochemical and 170 
structural diversity and by the geographic localisation of particular types.17 These factors complicate 171 
the design of both hydrolysis-evading molecules and inhibitors. KPC enzymes (Class A) dominate 172 
among Enterobacteriaceae in the Americas, China, Israel, Italy and Greece18 but OXA-48-like 173 
enzymes (Class D) are increasingly prominent in much of Europe as well as Africa and the Middle 174 
East.19  NDM types (Class B) predominate in the Indian subcontinent,20 but OXA-181, a sequence 175 
variant of OXA-48, is also frequent. Globalisation is eroding these geographic patterns and the UK, 176 
as an international crossroads, sees similar, albeit small, proportions of Enterobacteriaceae isolates 177 
– principally E. coli, Enterobacter spp. and Klebsiella spp. with NDM, KPC and OXA-48-like 178 
carbapenemases and a few with VIM and IMP MBLs (PHE, data on file). Also frequent are 179 
Enterobacteriaceae with low-level carbapenem resistance via combinations of AmpC or ESBL activity 180 
together with impermeability caused by porin loss,21 though these seem rarely to be implicated in 181 
outbreaks. Different carbapenemases, principally the acquired OXA-23, -24/-40, and -58 types, 182 
dominate in A. baumannii, though some isolates instead have ISAba1-mediated upregulation of 183 
chromosomal OXA-51 and a few have acquired metallo-enzymes.22,23  P. aeruginosa differs from 184 
other species in that most carbapenem resistance does not involve acquired carbapenemases. 185 
Rather, it arises via mutational loss of porin OprD, a mechanism that requires continued production 186 
of AmpC lactamase. Efflux augments resistance to meropenem, not imipenem.24 Minorities of 187 
carbapenem-resistant P. aeruginosa isolates have acquired carbapenemases, principally MBLs. 188 
 As outlined in the introduction, all the DBOs under development protect partner lactams 189 
against AmpC enzymes and class A lactamases, including KPC types.  OXA-48-like enzymes are 190 
less reliably inhibited, but can be circumvented by combining the DBO with an OXA-48-stable 191 
lactam (e.g ceftazidime, cefepime or aztreonam)5,7,8 or where the DBO has direct antibacterial 192 
activity, whilst none of the developmental combinations had activity, at accepted breakpoints of the 193 
unprotected carbapenems, against A. baumannii with OXA carbapenemases.   WCK 4234 thus 194 
represents a further advance in DBO development, potentiating carbapenems against 195 
Enterobacteriaceae with OXA-48 and -181 enzymes, P. aeruginosa with OXA-181 and, crucially, 196 
Acinetobacter spp. with OXA-23, -24/-40, upregulated -51-like, and -58 enzymes.  197 
 Besides this unique activity against strains with Class D carbapenemases, WCK 4234 198 
behaved like other DBOs,1,25 in potentiating its partner drugs against Enterobacteriaceae (i) with 199 
combinations of AmpC or ESBL activity and impermeability, (ii) P. aeruginosa with AmpC and (iii) 200 
Enterobacteriaceae with KPC carbapenemases.  In most cases the MICs of imipenem and 201 
meropenem were reduced below those of ceftazidime-avibactam, though this advantage may be 202 
offset by the high breakpoint (8+4 mg/L) assigned to ceftazidime-avibactam.  Generalised weak 203 
potentiation of imipenem –less so meropenem– was seen for imipenem against P. aeruginosa, 204 
probably reflecting the fact that chromosomal AmpC in this species, whether inducible or 205 
derepressed, gives some protection against this carbapenem.15 Similar generalised potentiation of 206 
imipenem against P. aeruginosa is seen with relebactam9 and AmpC-inhibiting penems and 207 
monobactams.26,27 208 
 In many cases – exceptions were a few Enterobacteriaceae with combinations of AmpC and 209 
impermeability or KPC enzymes, several P. aeruginosa groups and A. baumannii with OXA-24/40 or, 210 
for meropenem only, with OXA-58 enzymes – even the highest MICs of carbapenems-WCK 4234 211 
combinations were within the current CLSI and EUCAST breakpoints for the unprotected molecules, 212 
suggesting significant potential utility.  Except in the case of A. baumannii with OXA-58 enzymes, 213 
which are uncommon, there was little difference in performance between the imipenem and 214 
meropenem combinations, meaning that partner decisions will best be predicated on chemical 215 
stability, easy of formulation, dosing flexibility, scope for prolonged infusion and resistance to 216 
inactivation renal dehydropeptidase, rather than microbiological spectrum.  These factors support 217 
meropenem as a partner. 218 
 219 
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Table 1.  Species distribution in relation to resistance mechanism among test isolates of Enterobacteriaceae 
Mechanism Enterobacter spp. E.  coli Klebsiella spp. Grand Total 
AmpC 5 5 6 16 
AmpC + Impermeability 13 11 11 35 
ESBL 5 6 5 16 
ESBL + Impermeability 11 11 10 32 
KPC 11 9 11 31 
MBLa 5 5 5 15 
OXA-181  6 5 11 
OXA-48 10 5 5 20 
Susceptible control 5 5 5 15 
Grand Total 65 63 63 191 
 
a Six isolates with VIM enzymes, 9 with NDM types 
 
 
 
 
 
 
Table 2: Summary MIC parameters (mg/L) for WCK 4234 combinations and comparators  
 n IMP IMP 
 + WCK 4 
IMP  
+ WCK 8 
MEM MEM  
+ WCK 4 
MEM 
 + WCK 8 
CIP CAZ CAZ  
+ AVI4 
ERT 
Enterobacteriaceae            
Controls GM 15 0.26 0.14 0.15 0.02 0.02 0.02 0.03 0.43 0.16 0.04 
      Range  0.12-0.5 0.12-0.25 0.12-0.25 <0.03 <0.03 <0.03 0.008-0.25 0.12-1 0.03-0.5 <0.06 
AmpC Carb S GM 16 0.57 0.19 0.18 0.07 0.02 0.02 BM 86.7 0.37 0.38 
      Range  0.25-2 0.12-0.5 0.12-0.25 0.06-0.12 <0.06 <0.06 0.016->128 64->128 0.12-1 0.12-1 
AmpC + Imperm. GM 35 3.2 0.42 0.32 1.5 0.12 0.10 BM 107.2 0.83 15.7 
      Range  1-32 0.12-2 0.12-2 0.12-16 0.016-2 0.016-2 0.03->128 32->128 <0.03-32 2-128 
ESBL CarS GM 16 0.28 0.19 0.16 0.05 0.03 0.02 BM 43.34 0.23 0.13 
      Range  0.12-1 0.12-0.5 0.12-0.5 0.03-0.5 <0.016-0.5 <0.016-0.06 0.03->128 2->128 <0.03-1 <0.016-2 
ESBL + Imperm. GM 32 1.3 0.33 0.28 2.0 0.11 0.09 BM 74.5 0.69 12.1 
      Range  0.25-4 0.12-2 0.12-1 0.25-16 <0.016-1 <0.016-0.5 <0.016->128 2->128 0.12-8 2-64 
KPC GM 31 64.0 0.86 0.60 53.5 0.15 0.10 BM 83.7 0.95 97.9 
      Range  16->128 0.12-4(16) a 0.12-8 (32) 8->128 0.03-4(64) <0.016-2(64) <0.016->128 16->128 0.03-4 (>128) 64->128 
OXA-48 GM 20 15.5 0.32 0.27 9.85 0.06 0.06 BM BM 0.54 38.1 
      Range  4-128 0.12-1 0.12-0.5 2-128 <0.016-0.25 <0.016-0.5 <0.016->128 1->128 0.25-1 4->128 
 n IMP IMP 
 + WCK 4 
IMP  
+ WCK 8 
MEM MEM  
+ WCK 4 
MEM 
 + WCK 8 
CIP CAZ CAZ  
+ AVI4 
ERT 
OXA-181 GM 11 19.0 0.35 0.31 17.0 0.13 0.10 67.8 53.9 1.12 48.0 
      Range  4-128 0.12-2 <0.03-2 1-128 <0.016-0.5 <0.016-0.5 1-128 0.5-128 0.12-4 4-128 
MBL GM 15 67.0 67.0 67.0 70.2 58.4 58.4 BM 122.3 97.1 84.5 
      Range  16->128 16->128 16>128 8->128 8->128 8->128 <0.016->128 64->128 16->128 16->128 
P. aeruginosa            
Controls GM 20 1.0 0.36 0.26 0.21 0.10 0.08 0.26 1.6 1.2 - 
      Range  0.25-2 <0.06-1 0.12-0.5 0.06-2 <0.016-1 <0.016-1 0.03-4 0.5-8 0.25-2 - 
OprD loss GM 12 19.0 8.0 6.0 4.8 4.0 4.0 0.28 2.4 2.2 - 
      Range  8-32 4-16 2-8 4-8 2-8 2-8 0.12-2 2-4 1-4 - 
AmpC CarS GM 10 1.7 0.71 0.57 0.81 0.46 0.35 BM 55.7 5.3 - 
      Range  0.5-4 0.25-2 0.12-1 0.12-2 0.06-2 0.03-1 0.12-32 16->128 4-16 - 
AmpC + OprD loss GM 10 26.0 6.1 3.7 13.9 3.0 1.7 1.9 84.5 4.0 - 
      Range  16-32 1-32 0.5-16 8-16 (128) 0.5-8 0.12-8 0.12-32 32-128 2-8 - 
Efflux GM 15 2.5 1.6 1.3 3.0 2.6 2.2 0.41 4.8 4.2 - 
      Range  0.12-32 0.12-16 0.06-16 0.06-32 <0.016-32 <0.016-32 0.03-1 0.03-64 0.03-16 - 
            
 n IMP IMP 
 + WCK 4 
IMP  
+ WCK 8 
MEM MEM  
+ WCK 4 
MEM 
 + WCK 8 
CIP CAZ CAZ  
+ AVI4 
ERT 
 
Cystic fibrosis GM 
16 
26.9 9.1 6.4 21.7 8.0 6.4 4.0 83.1 38.1 - 
      Range  2->128 0.12-128 <0.06-128 0.25-128 0.12-128 0.03-128 1-32 8->128 4->128 - 
OXA ESBLs GMb 6 3.2 1.3 1.0 2.2 1.6 1.6 2.2 BM BM - 
      Range  2-32 0.5-8 0.5-8 1-8 1-4 1-4 0.25-16 4->128 2->128 - 
OXA-48 GM 2 too few too few too few too few too few too few too few too few too few - 
      Range  >128 8-16 4-8 64-128 2-4 2-4 16 2-4 2-4 - 
MBL GM 5 73.5 73.5 73.5 42.2 42.2 42.2 BM 64.0 73.5 - 
      Range  32-128 32-128 32-128 16-128 16-128 16-128 0.25-128 16->128 32->128  
Acinetobacter            
Controls GM 5 0.29 0.25 0.25 0.25 0.22 0.22 0.33 4.00 4.59 3.03 
      Range  0.12-0.5 0.12-1 0.12-1 0.12-0.5 0.12-0.5 0.12-0.5 0.25-0.5 2-8 2-16 2-4 
AmpC 10 1.1 0.54 0.44 1.2 0.81 0.87 BM 73.5 29.9 12.1 
      Range  0.5-2 0.25-1 0.25-1 0.25-2 0.25-2 0.25-2 0.5-128 8->128 8-64 8-32 
OXA-23 10 48.50 2.14 1.62 45.25 1.74 1.15 103.98 128.07 51.98 >128 
      Range  16-128 0.25-4 0.5-4 32-128 0.5-8 0.5-4 32->128 >128 8-128 >128 
 n IMP IMP 
 + WCK 4 
IMP  
+ WCK 8 
MEM MEM  
+ WCK 4 
MEM 
 + WCK 8 
CIP CAZ CAZ  
+ AVI4 
ERT 
OXA-24/40 10 59.7 4.9 2.8 78.8 5.7 3.0 BM 48.5 19.7 128.1 
      Range  16-128 1-32 0.5-16 32->128 1-32 0.5-16 2->128 8-128 4-32 >128 
OXA-51–ISAba1 10 16.0 0.87 0.62 36.8 1.2 1.2 90.5 104.0 34.3 >128 
      Range  8-32 0.5-4 0.25-2 16->128 0.25.4 0.5-4 4-128 16->128 16->128 >128 
OXA-58 10 39.4 2.1 1.4 19.7 3.0 2.6 68.6 >128 90.56 104.00 
      Range  32-64 1-4 0.5-4 8-32 0.5-16 0.5-16 16->128 >128 16->128 64->128 
MBL (NDM) 5 >128 >128 >128 >128 >128 >128 BM >128 >128 >128 
      Range  >128 >128 >128 >128 >128 >128 0.25-128 >128 >128 >128 
 
Abbreviations: AVI, avibactam; BM, bimodal distribution, invalidating geometric mean; Carb S, susceptible to carbapenems at CLSI breakpoints; CAZ, 
ceftazidime; CIP, ciprofloxacin; ERT, ertapenem; GM, geometric mean;  IMP, imipenem; MEM, meropenem, WCK 4/WCK 8, WCK 4234 at 4 or 8 mg/L 
respectively.      
a Single isolate with MIC far outside the general range; b Isolates with ESBL variants belonging to the OXA-2 and -10 families 
Underlining highlights cases where the geometric mean MIC for an inhibitor combination was at least four-fold lower than for the unprotected -lactam 
Table 3.  MIC distributions of carbapenems and their WCK 4234 combinations for groups of isolates with KPC and Class D carbapenemases 
 No. isolates with indicated MIC (mg/L) 
 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 >128 
Enterobacteriaceae KPC                
Imipenem           2 9 7 8 5 
IMP+WCK 4234, 4 mg/L    1 8 6 7 4 3  2     
IMP+WCK 4234, 8 mg/L    2 12 6 5 3 1 1  1    
Meropenem          2 3 8 6 6 6 
MEM+WCK 4234, 4 mg/L  11 6 1 4 3 2 2 1    1   
MEM+WCK 4234, 8 mg/L 1 13 5 2 4 3  1     1   
                
Enterobacteriaceae OXA-48                
Imipenem         6 4 2 4 1 3  
IMP+WCK 4234, 4 mg/L    4 6 9 1         
IMP+WCK 4234, 8 mg/L    5 8 7          
Meropenem        5 3 2 5 2 2 1  
MEM+WCK 4234, 4 mg/L 1 6 7 4 2           
MEM+WCK 4234, 8 mg/L 1 7 5 5 1 1          
                
Enterobacteriaceae OXA-181                
Imipenem         4 1  4 1 1  
IMP+WCK 4234, 4 mg/L    3 4 2  2        
IMP+WCK 4234, 8 mg/L   1 3 3 2  2        
Meropenem       2  3   2 2 2  
 No. isolates with indicated MIC (mg/L) 
 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 >128 
MEM+WCK 4234, 4 mg/L 1 2  3 3 2          
MEM+WCK 4234, 8 mg/L 1 2 1 5 1 1          
                
P. aeruginosa OXA-48                
Imipenem              1 1 
IMP+WCK 4234, 4 mg/L          1 1     
IMP+WCK 4234, 8 mg/L         1 1      
Meropenem             1 1  
MEM+WCK 4234, 4 mg/L        1 1       
MEM+WCK 4234, 8 mg/L        1 1       
                
Acinetobacter OXA-23                
Imipenem           1 3 5 1  
IMP+WCK 4234, 4 mg/L     1  1 3 5       
IMP+WCK 4234, 8 mg/L      2  7 1       
Meropenem            6 3 1  
MEM+WCK 4234, 4 mg/L      1 2 6  1      
MEM+WCK 4234, 8 mg/L      1 7 1 1       
                
Acinetobacter OXA-24/40                
Imipenem           1 2 4 3  
IMP+WCK 4234, 4 mg/L       3 1 1 1 3 1    
 No. isolates with indicated MIC (mg/L) 
 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 >128 
IMP+WCK 4234, 8 mg/L      2 2  2 3 1     
Meropenem            2 3 3 2 
MEM+WCK 4234, 4 mg/L       3 1  2 2 2    
MEM+WCK 4234, 8 mg/L      2 2  2 2 2     
                
Acinetobacter ISAba1-OXA-51                
Imipenem          4 2 4 4   
IMP+WCK 4234, 4 mg/L      6 1 2 1       
IMP+WCK 4234, 8 mg/L     1 6 2 1        
Meropenem           4 1 4  1 
MEM+WCK 4234, 4 mg/L     1 1 4 3 1       
MEM+WCK 4234, 8 mg/L      1 7 1 1       
                
Acinetobacter OXA-58                
Imipenem            7 3   
IMP+WCK 4234, 4 mg/L       2 5 3       
IMP+WCK 4234, 8 mg/L      1 5 2 2       
Meropenem          2 3 5    
MEM+WCK 4234, 4 mg/L      1 1 1 6  1     
MEM+WCK 4234, 8 mg/L      1 2 1 5  1     
 
 
Table 4.  MICs of carbapenem-WCK 4234 combinations and comparators against AmpC and OprD mutants of P. aeruginosa 
   MIC (mg/L)  
 
 Designation and 
phenotype 
IMI IMI  
+ WCK 4 
IMI  
+ WCK 8 
MEM MEM 
 + WCK 4 
MEM  
+ WCK 8 
CIP CAZ CAZ  
+ AVI4 
ERT 
P. aeruginosa 1405-con 4 1 1 1 0.5 0.25 0.25 128 8 32 
 1405 -con OprD- 32 8 8 16 8 8 0.5 128 8 >128 
 1405 -def 0.5 0.25 0.25 0.25 0.25 0.25 0.5 8 2 4 
 1405 -def OprD- 1 1 1 4 4 4 0.25 2 2 16 
                       
P. aeruginosa 2297 2 1 0.5 0.5 0.25 0.25 0.25 2 2 4 
 2297 -con 2 0.5 0.5 0.5 0.25 0.125 0.25 64 4 8 
 2297 -con OprD- 16 8 4 8 4 4 0.25 128 4 128 
 2297 -def 0.25 0.25 0.25 0.25 0.125 0.125 0.25 2 2 2 
 2297 –def OprD- 4 2 2 4 2 2 0.25 2 2 32 
 
Strain numbers suffixed –CON, derepressed for AmpC; -DEF, deficient for AmpC; OprD-, deficient for porin OprD; un-suffixed numbers inducible for AmpC.  
Other abbreviations are as in Table 2
Figure 1.  Structure of WCK 4234  
Figure 1 
 
 
 
 
